CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


standard western medicine treatmentWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug711 Daily Monitoring Wiki 1.00
drug558 Chinese medicine treatment Wiki 1.00
drug2708 YinHu QingWen Decoction(low dose) Wiki 1.00
drug2707 YinHu QingWen Decoction Wiki 1.00
drug843 Emotional Support Plan Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D002659 Child Development Disorders, Pervasive NIH 0.58
D001321 Autistic Disorder NIH 0.50
D000067877 Autism Spectrum Disorder NIH 0.41
D013315 Stress, Psychological NIH 0.21

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0000717 Autism HPO 0.50
HP:0000729 Autistic behavior HPO 0.41

There is one clinical trial.

Clinical Trials


1 Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally. Given no specific antiviral therapy for CoVID-19 infection and the availability of Yinhu Qingwen Decoction as a potential antiviral Chinese medicine based on vivo antiviral studies in CoVID-19, this randomized,three-arm controlled, single-blind trial will evaluate the efficacy and safety of Yinhu Qingwen Decoction (Granula) in patients hospitalized with mild or common CoVID-19 respiratory disease.

NCT04278963 CoVID-19 Chinese Medicine Drug: YinHu QingWen Decoction Drug: YinHu QingWen Decoction(low dose) Other: Chinese medicine treatment Other: standard western medicine treatment

Primary Outcomes

Description: The clinical recovery time is defined as the time from initiation of study treatment (active or placebo) until normalisation of fever, respiratory rate, and oxygen saturation, and alleviation of cough, sustained for at least 72 hours. Normalisation and alleviation criteria: (1) Fever: ≤36.6°C or -axilla, ≤37.2 °C oral or ≤37.8°C rectal or tympanic;(2)Respiratory rate - ≤24/minute on room air; 3) Oxygen saturation - >94% on room air; (4) Cough - mild or absent on a patient reported scale (cough symptoms score ≤ 2 points).

Measure: Mean clinical recovery time (hours)

Time: up to 28 days

Secondary Outcomes

Measure: Time to CoVID-19 RT-PCR negative in upper respiratory tract specimen

Time: up to 28 days

Measure: Change (reduction) in CoVID-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.

Time: up to 28 days

Measure: Time to defervescence (in those with fever at enrolment)

Time: up to 28 days

Measure: Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)

Time: up to 28 days

Measure: Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)

Time: up to 28 days

Measure: Frequency of requirement for supplemental oxygen or non-invasive ventilation

Time: up to 28 days

Description: Defined as: SPO2≤ 93% on room air or PaO2/FiO2≤ 300mmHg and requirement for supplemental oxygen or more advanced ventilator support.

Measure: Frequency of respiratory progression

Time: up to 28 days

Description: Severe case is defined as respiratory rate ≥30/minute on room air;or Oxygen saturation - ≤94% on room air;or PaO2/FiO2≤300mmHg.

Measure: Severe case incidence

Time: up to 28 days

Measure: Proportion of re-hospitalization or admission to ICU

Time: up to 28 days

Measure: All-cause mortality

Time: up to 28 days

Measure: Frequency of serious adverse events

Time: up to 28 days


No related HPO nodes (Using clinical trials)